ADIPOQ and endothelial dysfunction: Remarkably, ADIPOQ consistently showed downregulation in STEMI patients across both the acute and stabilization phases compared to TS, suggesting its potential as a diagnostic marker and underscoring its involvement in systemic inflammation and endothelial dysfunction.